Hoth Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HOTH research report →
Price Chart
About the company
Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. Its product pipeline focuses on potential treatments for indications including atopic dermatitis (also known as eczema), chronic wounds, psoriasis, asthma, and acne.
- CEO
- Robb Knie
- IPO
- 2019
- Employees
- 6
- HQ
- Hoboken, NY, US
Get TickerSpark's AI analysis on HOTH
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $10.62M
- P/E
- -0.91
- Fwd P/E
- 0.70
- PEG
- -0.03
- P/S
- 0.00
- P/B
- 1.89
- EV/EBITDA
- -0.67
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -199.23%
- ROIC
- -160.57%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-11,110,849
- Net Income
- $-12,469,302-52.3%
- EPS
- $-0.90+29.7%
- OCF Growth
- -40.5%
- FCF Growth
- -40.5%
- 52W High
- $2.45
- 52W Low
- $0.49
- 50D MA
- $0.80
- 200D MA
- $1.11
- Beta
- 0.53
- RSI (14)
- 42
- Avg Volume
- 10.56M
No earnings-call transcripts are available for HOTH yet.
- Free Float
- 95.8%
- Shares Outstanding
- 13.26M
- Float Shares
- 12.71M
of shares held by institutions
22 13F filers
Buy/sell ratio 1.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 214.01K | 0 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 7, 22 | Pavell Jeff | other | 0 |
| Sep 19, 22 | Knie Robb | buy | 10,000 |
| Sep 16, 22 | Knie Robb | buy | 10,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our HOTH coverage
Recent articles, reports, and earnings notes.
No research on HOTH yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate HOTH report →Why Hoth Therapeutics (HOTH) Stock Is Surging After Hours Today
feeds.benzinga.com · May 28
Hoth Therapeutics Becomes Rocket One Inc. (Nasdaq: RKTO), Targeting the Space Economy with Next-Generation Nanomagnetic AI Chip Technology and Ultra-Low-Power, Radiation-Tolerant Computing for Space and Defense Applications
prnewswire.com · May 27
Hoth Therapeutics Awarded U.S. Patent for Cancer-Fighting HT-KIT Oncology Platform
prnewswire.com · May 26
AI Chip Energy Efficiency: Hoth Therapeutics Restructures as Rocket One Inc. to Enter the AI Semiconductor Infrastructure Market with Acquisition of Exclusive Rights to Next Generation AI Semiconductor Acceleration Technology Built on Non-Volatile Nanomagnetic Semiconductor Architecture
prnewswire.com · May 19
Hoth Therapeutics Secures European Authorization in Spain for HT-001 Phase 2a Trial as Interim Data Show Strong Efficacy in Cancer Patients
prnewswire.com · May 5
Hoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene and Activates Fat-Burning Pathways, Outperforming Semaglutide
prnewswire.com · Apr 14
Hoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene and Activates Fat-Burning Pathways, Outperforming Semaglutide
prnewswire.com · Apr 13
Hoth Therapeutics Announces Closing of $2.0 Million Registered Direct Offering
prnewswire.com · Apr 2
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.